Dasatinib plus quercetin senolytic therapy: the 2024-2025 human trial update

Senolytics — drugs that selectively eliminate senescent cells — were the most discussed aging-biology breakthrough of the late 2010s. The combination of the prescription leukemia drug dasatinib with the flavonoid quercetin (D+Q) has been the lead human regimen. Five years and a handful of early-phase trials later, the field has demonstrated feasibility and target engagement but has not yet shown clear clinical benefit. The supplement-aisle "senolytic" capsules sold to consumers are not what was studied.

The preclinical foundation

Zhu and Tchkonia at Mayo Clinic identified D+Q in 2015 using a bioinformatic screen for compounds predicted to disrupt the anti-apoptotic networks that allow senescent cells to persist [1]. In aged mice, intermittent D+Q dosing improved physical function, reduced osteoporosis, extended healthspan, and in some models extended lifespan modestly. The intermittent "hit-and-run" dosing schedule (one or two days per week or month) was crucial; continuous dosing did not reproduce the benefit.

The 2019 IPF feasibility trial

The first human D+Q senolytic trial was an open-label feasibility study in 14 patients with idiopathic pulmonary fibrosis. Patients received dasatinib 100 mg/day plus quercetin 1,250 mg/day for three days per week for three weeks. The treatment was feasible, with improvements in 6-minute walk distance and 4-meter gait speed; no placebo control was used [2]. A subsequent open-label study in 9 patients with diabetic kidney disease reported reduced senescent cell burden in adipose tissue and skin after 11 days of intermittent dosing [3].

The 2024-2025 randomized data

The first randomized placebo-controlled D+Q senolytic trial in humans, ALSENLITE, enrolled 60 older women at increased fracture risk and reported in 2024 a non-significant trend toward improvements in bone resorption markers and circulating SASP biomarkers, but no difference in primary skeletal endpoints over 20 weeks [4]. A 2024 Phase 2 trial in 48 patients with Alzheimer's disease (SToMP-AD) reported acceptable safety, target engagement (modest reductions in CSF senescence biomarkers), and no signal of cognitive benefit at 12 weeks [5]. The 2025 PEARLS trial in 130 frail older adults completed enrollment with results expected in late 2026.

Why supplement-aisle "senolytic" products are different

Consumer senolytic supplements typically contain fisetin (often 100-500 mg), quercetin, theaflavins, and proprietary polyphenol blends. None of these has been demonstrated as a single-agent senolytic in placebo-controlled human trials. Fisetin is in active Phase 2 testing for several indications; quercetin alone has never produced consistent senolytic effects in human trials and was used in D+Q only as a complementary agent. The doses used in the supplement market are generally below those used in the Mayo studies, and the dasatinib component (the prescription drug doing most of the senolytic work in the lab) is by definition absent from supplements [6].

The safety considerations

Dasatinib is FDA-approved for chronic myelogenous leukemia and acute lymphoblastic leukemia, with known adverse effects including pleural effusion, pulmonary hypertension, thrombocytopenia, and QT prolongation. The intermittent D+Q regimen used in research uses lower doses than oncology indications but is not without risk. Quercetin alone, at the doses studied (1-2 g/day), is generally well tolerated but interacts with CYP3A4 substrates and can potentiate warfarin. The combination should not be self-administered outside trial settings [7].

Bottom line

Senolytic therapy with dasatinib plus quercetin is a real research program with real preclinical foundation and ongoing human trials. As of 2026 it has not produced positive randomized efficacy data in any disease. Consumer senolytic supplements containing quercetin or fisetin alone are not equivalent to the Mayo Clinic regimen and have not been validated as senolytics in humans.